Brought to you by 
GenMark Diagnostics nets $25.7mm through its IPO
27 Apr 2012
Executive Summary
GenMark Diagnostics Inc. (formerly Osmetech; molecular diagnostic systems) has completed its initial public offering. It netted $25.7mm through the sale of 4.6mm common shares at $6 each, lower than the $8-10 range the company had expected.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Biosensors
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GenMark Diagnostics nets $25.7mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice